{"id":2057732,"date":"2023-10-06T10:52:02","date_gmt":"2023-10-06T14:52:02","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/moderna-to-begin-late-stage-trial-of-covid-flu-combo-vaccine\/"},"modified":"2023-10-06T10:54:40","modified_gmt":"2023-10-06T14:54:40","slug":"moderna-to-begin-late-stage-trial-of-covid-flu-combo-vaccine","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/moderna-to-begin-late-stage-trial-of-covid-flu-combo-vaccine\/","title":{"rendered":"Moderna starts final trial for COVID-Flu combo vaccine."},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"&quot;\"><div class=\"counts mashsbcount\">16<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Fmoderna-to-begin-late-stage-trial-of-covid-flu-combo-vaccine%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=2057732&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><blockquote>\n<h2>Moderna Advances to Late-Stage Trial of COVID-Influenza Combination Vaccine<\/h2>\n<p>Moderna\u2063 announced that it is progressing to the \u2063late stage trial of \u200bits COVID-influenza combination vaccine after obtaining positive results\u200b in preliminary trials. This comes \u200ddespite concerns about the safety of Moderna&#8217;s COVID-19 vaccine.<\/p>\n<p>A combination vaccine combines multiple vaccines into a \u2063single injection. Moderna&#8217;s mRNA-1083 combination vaccine, targeting influenza and\u2062 COVID-19, showed promising interim results\u200b in phase\u200d 1 and 2 trials, according\u2064 to the company&#8217;s press release\u2062 on Oct. 4.<\/p>\n<p>Now, Moderna is preparing \u2064for the phase 3\u2063 late-stage trial of the vaccine.<\/p>\n<\/blockquote>\n<h2>Related Stories<\/h2>\n<ul>\n<li>\n<h3><a href=\"http:\/\/www.theepochtimes.com\/health\/novavax-covid-vaccine-provides-little-protection-against-infection-study-5504065?ea_src=author_manual&#038;ea_med=related_stories\">Novavax COVID Vaccine Provides\u2062 Little Protection Against Infection: Study<\/a><\/h3>\n<p class=\"text-comp-caption\">10\/5\/2023<\/p>\n<\/li>\n<li>\n<h3><a href=\"http:\/\/www.theepochtimes.com\/us\/cdc-ends-covid-19-vaccination-cards-5504367?ea_src=author_manual&#038;ea_med=related_stories\">CDC Ends COVID-19 Vaccination\u200b Cards<\/a><\/h3>\n<p class=\"text-comp-caption\">10\/5\/2023<\/p>\n<\/li>\n<\/ul>\n<p>The preliminary trials compared Moderna&#8217;s mRNA-1083 combination vaccine with two influenza vaccines\u2014Fluarix and Fluzone\u200d HD.\u2063 The\u2064 combination\u200b vaccine was tested on\u2062 adults aged 50 \u2063to 64, \u200bwhile Fluzone \u200bHD is specifically designed for individuals \u200baged 65 to 79.<\/p>\n<p>According to Moderna, the preliminary trials demonstrated that mRNA-1083 produced antibody levels\u2063 in the blood \u2062that were similar to or higher than the licensed influenza vaccines. It also\u200c showed comparable antibody levels to Moderna&#8217;s COVID-19 vaccine.<\/p>\n<p>The adverse reactions\u200b observed with mRNA-1083 were\u200c found to be similar to those of the Spikevax vaccine. The majority of adverse reactions \u200bwere \u2064of mild to moderate severity, with less than 4 percent categorized as \u2063severe.<\/p>\n<p>Moderna stated \u2063that no new safety concerns were \u200bidentified for mRNA-1083 \u2062compared to the standalone vaccines.<\/p>\n<h2>Moderna&#8217;s Combo Vaccine Push<\/h2>\n<p>Moderna plans to initiate \u200cthe phase 3 trial of mRNA-1083\u2064 in adults aged 50 and above this\u200c year, with \u2064the goal of obtaining regulatory approval for the vaccine by 2025.<\/p>\n<div class=\"post-figure\" style=\"margin-left:0;margin-right:0;max-width:1200px\">\n<figure style=\"width:640px;margin-left:auto;margin-right:auto\" class=\"alignnone\"><figcaption>A <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/covid-19-vaccine-found-in-dead-people-study\/\" title=\"COVID-19 vaccine discovered in deceased individuals: Study\">health care worker prepares<\/a> the Moderna coronavirus vaccine \u2062at Lestonnac Health Clinic in Orange, \u200dCalif.,\u2064 on March 9, 2021. (John\u200d Fredricks\/The Epoch Times)<\/figcaption><\/figure>\n<\/div>\n<p>&#8220;Combination vaccines offer an important opportunity to improve consumer \u200dand provider \u200bexperience, increase\u2063 compliance with public health recommendations, and\u200d deliver value for \u200dhealthcare\u200c systems,&#8221; said Stephane Bancel, CEO of Moderna.<\/p>\n<p>Moderna\u200d estimates that the U.S. <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/moderna-to-begin-late-stage-trial-of-covid-flu-combo-vaccine\/\" title=\"Moderna starts final trial for COVID-Flu combo vaccine.\">influenza market requires 150 million doses annually<\/a>, with an estimated market of 50 million to 100 million doses for the fall\u2062 of 2023. The company \u2064also anticipates\u2062 that the\u200c market for \u2064COVID-19 vaccines will eventually rival that of influenza vaccines in the United States.<\/p>\n<p>According to data from the U.S. Centers for \u2064Disease Control\u200d and Prevention \u2064(CDC), new COVID-19\u2062 hospital admissions \u200cin the country are currently at\u2062 a low \u200clevel compared to previous\u200b years.<\/p>\n<h2>COVID-19 Vaccine Dangers<\/h2>\n<p>While COVID-19 vaccines are widely promoted as crucial to healthcare, several studies\u200b are raising concerns\u200b about their safety. One study even suggests a link\u200d between COVID-19\u200b booster shots and\u2063 heart damage.<\/p>\n<p>A study published in the European Journal of Heart Failure found that Moderna&#8217;s mRNA-1273 COVID shot was associated \u2064with\u2064 an increased risk\u2063 of myocardial injury,\u200b affecting about 1 in 35 individuals or 2.8 percent. This rate is higher than what would typically be expected in a healthy population.<\/p>\n<div class=\"my-5\">&#8220;According to current knowledge, the cardiac muscle can&#8217;t regenerate, \u200dor only to a very limited degree\u200b at best. So it&#8217;s possible that repeated booster \u2063vaccinations\u200c every \u200byear could cause\u200d moderate \u2064damage to the heart muscle cells,&#8221; \u200csaid Professor Christian Mueller,\u2062 a cardiologist and the lead researcher of the study.<\/div>\n<p>In his testimony to the European Parliament, cardiologist Dr. Peter McCullough called\u2064 for \u200bthe removal of COVID-19 vaccines from the market, citing concerns about their safety. He \u200demphasized the potential risks \u200cassociated with the spike protein found in the vaccines.<\/p>\n<div class=\"post-figure\" style=\"margin-left:0;margin-right:0;max-width:1200px\">\n<figure style=\"width:640px;margin-left:auto;margin-right:auto\" class=\"alignnone\"><figcaption>Cardiologists Dr. Aseem Malhotra (L) and Dr. Peter \u2062McCullough in Dallas on Nov. 29, 2022. (Bao Qiu\/The Epoch\u200d Times)<\/figcaption><\/figure>\n<\/div>\n<p>These findings raise questions about the safety and efficacy of COVID-19 vaccines, despite their widespread use. It is important\u200c to \u200dconsider all available \u2063information and ongoing research when making decisions\u200d about vaccination.<\/p>\n<p><em>Zachary Stieber contributed to this report.<\/em><\/p>\n<p> <\/p>\n<h2> What \u2064are\u2062 the preliminary trial results for Moderna&#8217;s mRNA-1083 \u200ccombination vaccine\u2063 in terms \u200bof \u2063antibody levels?<\/h2>\n<p><span>  Rom the Centers \u2064for Disease Control \u2063and Prevention (CDC), \u2062influenza and COVID-19 are both <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/uk-prime-minister-aims-to-raise-smoking-age-by-a-year-every-year\/\" title=\"UK PM plans to increase smoking age annually.\">significant public health threats<\/a>. Each year, influenza causes\u200c millions of illnesses, hospitalizations, and deaths worldwide. The ongoing COVID-19 pandemic has \u2064further emphasized the \u2064need \u200bfor effective vaccines to \u2062protect\u200c against respiratory illnesses.<\/p>\n<p>Moderna&#8217;s mRNA-1083 combination vaccine aims to address\u200c this urgent need by\u2063 targeting both influenza\u200c and COVID-19. The preliminary trials for mRNA-1083 have shown promising results, with the vaccine producing\u200b antibody levels in the blood that are comparable to or higher \u2062than licensed influenza vaccines. Additionally, the antibody levels for mRNA-1083\u200c were similar \u2064to\u2062 Moderna&#8217;s COVID-19 vaccine, \u2064indicating its potential effectiveness against both\u200d viruses.<\/p>\n<p>The\u200d safety \u200dprofile of mRNA-1083 has been assessed and found \u2063to be similar to that of \u200dthe Spikevax\u2062 vaccine. Adverse reactions \u2062were mainly \u2064mild \u2062to moderate, with only a small percentage categorized as severe. \u2062Importantly, no new safety concerns were identified\u200b for mRNA-1083 compared\u2063 to the \u200dstandalone\u200b vaccines.<\/p>\n<p>Building on \u2062the\u200b positive \u2062outcomes of the preliminary\u2062 trials, \u200cModerna plans\u200d to proceed \u200dwith \u2064the phase 3 late-stage trial of mRNA-1083 in adults aged 50 and above. The company aims to obtain regulatory approval \u2062for the\u200b vaccine \u200bby 2025, highlighting their commitment to providing a safe and effective combination vaccine\u200c for the general population.<\/p>\n<p>The CEO \u2062of Moderna, Stephane Bancel, \u200drecognizes the importance of combination \u2063vaccines in enhancing the overall healthcare \u2063experience and \u2064increasing compliance with public\u200d health recommendations. \u200bCombination vaccines offer the opportunity to streamline vaccination efforts,\u2062 making it \u2063easier for individuals\u200d to\u200d receive the necessary\u2064 protection against multiple diseases. Furthermore, combination vaccines can potentially reduce the burden on healthcare systems and contribute to a more\u2063 efficient allocation of\u200c resources.<\/p>\n<p>Moderna&#8217;s mRNA-1083\u200c combination vaccine holds significant market potential. The U.S. influenza market alone requires millions \u200cof\u200b doses annually, and the anticipated market for COVID-19 vaccines \u2062is expected to\u2063 rival that of influenza vaccines in\u2064 the future. By \u200baddressing the need\u200b for both influenza \u2062and \u200bCOVID-19 protection, Moderna aims\u200b to \u200bplay a crucial role \u200din mitigating \u200dthe\u200b impact \u200dof these respiratory\u200d illnesses on public health.<\/p>\n<p>In conclusion, Moderna&#8217;s progress \u2062in advancing to the late-stage trial of the mRNA-1083 combination vaccine is a promising \u2064development in the\u200c fight against influenza and COVID-19. The positive results from preliminary trials underscore the potential effectiveness of this \u2064vaccine in producing robust immune \u200bresponses. As\u2063 Moderna continues its efforts to\u200c obtain regulatory approval, the mRNA-1083 combination vaccine could\u2063 significantly contribute to improving public health outcomes \u2064and reducing the burden of respiratory \u200cdiseases in\u2064 the future.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>administered in a single shot. Moderna&#8217;s COVID-influenza combination vaccine has shown promising results in preliminary trials, prompting the company to proceed with late-stage trials. However, concerns have been raised regarding the safety of Moderna&#8217;s COVID-19 vaccine.<\/p>\n","protected":false},"author":186,"featured_media":2057733,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[543],"tags":[],"class_list":["post-2057732","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-the-epoch-times"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2057732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/186"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=2057732"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2057732\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/2057733"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=2057732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=2057732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=2057732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}